Severe peripheral nerve and muscle injuries are a highly prevalent condition for both civilians and military personnel caused by traffic accidents, work injuries, acts of violence, as well as combat events. Peripheral nerve injury is a substantial problem that annually affects more than several millions of people all over the world. For most patients who suffer from severe peripheral nerve injuries spontaneous recovery may eventually occur, but it is slow and frequently incomplete. Effective posttraumatic nerve repair and decrease or prevention of corresponding muscle atrophy remain a great challenge to restorative medicine. A certain clinical interest began to appear in the potential therapeutic value of laser phototherapy (new name – laser photobiomodulation) for regeneration enhancement of injured peripheral nerve as well as for restoration or prevention of denervated muscle atrophy. Although a pioneering report regarding the effects of laser phototherapy on the regeneration of traumatically injured peripheral nerves was published in the late 1970s,1 it is only since the end of past century - early 2000s that scientific interest in this therapeutic approach for neural rehabilitation has appeared, leading to publication of several studies that have shown positive effects of phototherapy on peripheral nerve regeneration.2 [...]
{"title":"Phototherapy (photobiomodulation) for peripheral nerve and muscle injury","authors":"S. Rochkind","doi":"10.4081/ltj.2023.324","DOIUrl":"https://doi.org/10.4081/ltj.2023.324","url":null,"abstract":"Severe peripheral nerve and muscle injuries are a highly prevalent condition for both civilians and military personnel caused by traffic accidents, work injuries, acts of violence, as well as combat events. \u0000Peripheral nerve injury is a substantial problem that annually affects more than several millions of people all over the world. For most patients who suffer from severe peripheral nerve injuries spontaneous recovery may eventually occur, but it is slow and frequently incomplete. Effective posttraumatic nerve repair and decrease or prevention of corresponding muscle atrophy remain a great challenge to restorative medicine. A certain clinical interest began to appear in the potential therapeutic value of laser phototherapy (new name – laser photobiomodulation) for regeneration enhancement of injured peripheral nerve as well as for restoration or prevention of denervated muscle atrophy. Although a pioneering report regarding the effects of laser phototherapy on the regeneration of traumatically injured peripheral nerves was published in the late 1970s,1 it is only since the end of past century - early 2000s that scientific interest in this therapeutic approach for neural rehabilitation has appeared, leading to publication of several studies that have shown positive effects of phototherapy on peripheral nerve regeneration.2 [...]","PeriodicalId":17981,"journal":{"name":"Laser therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45078591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antonio Leccisotti, Stefania V. Fields, G. De Bartolo, Christian Crudale
A femtosecond laser creates an intrastromal lenticule while the eye is immobilized by vacuum in refractive corneal lenticule extraction to correct myopia. Suction loss has a 0.72% overall incidence and may result in an incomplete cut; the procedure can then be completed using the same or different techniques. While previous laser platforms used corneal suction, the recent lenticule extraction (CLEAR) application for the Ziemer Z8 femtosecond laser (Ziemer Group, Port) uses scleral suction; studies on suction loss with this vacuum system are lacking. A total of 652 eyes from 357 CLEAR patients were thus included in a consecutive, single-institution, retrospective study. Suction loss occurred in three patients’ left eyes (0.46%) due to a strong involuntary eyelid contraction. After an early suction loss in patient #1, the procedure was successfully repeated with the same parameters. Suction loss occurred after the completion of the posterior cut and at 44% of the anterior cut in patient #2. The laser procedure appeared to have been completed in patient #3, but the lenticule had not been delineated temporally due to false suction on the conjunctiva. Thin flap femtosecond laser in situ keratomileusis (LASIK) was used to complete the refractive procedure in patients #2 and #3. Uncorrected distance visual acuity was 20/20 or better in all three eyes at 6 months. Finally, suction loss during CLEAR was uncommon and had a favorable prognosis. Repeat lenticule extraction or femtosecond LASIK can be performed on the same day to complete the treatment.
{"title":"Incidence and outcome of suction loss during corneal lenticule extraction with the femtosecond laser application CLEAR","authors":"Antonio Leccisotti, Stefania V. Fields, G. De Bartolo, Christian Crudale","doi":"10.4081/ltj.2023.322","DOIUrl":"https://doi.org/10.4081/ltj.2023.322","url":null,"abstract":"A femtosecond laser creates an intrastromal lenticule while the eye is immobilized by vacuum in refractive corneal lenticule extraction to correct myopia. Suction loss has a 0.72% overall incidence and may result in an incomplete cut; the procedure can then be completed using the same or different techniques. While previous laser platforms used corneal suction, the recent lenticule extraction (CLEAR) application for the Ziemer Z8 femtosecond laser (Ziemer Group, Port) uses scleral suction; studies on suction loss with this vacuum system are lacking. A total of 652 eyes from 357 CLEAR patients were thus included in a consecutive, single-institution, retrospective study. Suction loss occurred in three patients’ left eyes (0.46%) due to a strong involuntary eyelid contraction. After an early suction loss in patient #1, the procedure was successfully repeated with the same parameters. Suction loss occurred after the completion of the posterior cut and at 44% of the anterior cut in patient #2. The laser procedure appeared to have been completed in patient #3, but the lenticule had not been delineated temporally due to false suction on the conjunctiva. Thin flap femtosecond laser in situ keratomileusis (LASIK) was used to complete the refractive procedure in patients #2 and #3. Uncorrected distance visual acuity was 20/20 or better in all three eyes at 6 months. Finally, suction loss during CLEAR was uncommon and had a favorable prognosis. Repeat lenticule extraction or femtosecond LASIK can be performed on the same day to complete the treatment.","PeriodicalId":17981,"journal":{"name":"Laser therapy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41562501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Skin laxity in the periorbital region is a common problem that is usually treated surgically. This is not only invasive, but it also increases the risks for the patient and can result in scarring. Innovative therapies involving the use of the most recent generation of interstitial lasers allow for safe, minimally invasive, and effective intervention in patients suffering from blepharochalasis and periorbital bags. A 100% Made in Italy intra-tissue laser lifting technology, in particular, delivers energy to the subcutaneous tissue via laser fibers as small as 200/300 microns, ensuring a targeted release of energy and allowing the formation of new collagen while decreasing skin laxity. The purpose of this study is to assess the effect of an interstitial laser using optical microfibers on 5 patients aged 30 to 60 years. Following anesthesia (Lidocaine and Adrenaline), the treatment was performed using an endotissue laser with a wavelength of 1470 nm. The cumulative energy delivered by the laser by using 300-micron disposable fibers is equal to 200 Joules for each lid, with an infrared thermometer confirming an increase in skin temperature not exceeding 40°C. Over the next six months, patients experienced optimal results with no visible skin signs. In conclusion, we can state that intra-tissue laser lifting can be an effective strategy for the treatment of periorbital laxity, resulting in a decrease in dermal laxity and greater skin homogeneity while ensuring high precision, the absence of superficial incisions, rapid recovery, and optimal results.
{"title":"Real-life efficacy interstitial laser therapy treating laxity of the periorbital region","authors":"L. Zattoni, Alessia Forlin","doi":"10.4081/ltj.2023.321","DOIUrl":"https://doi.org/10.4081/ltj.2023.321","url":null,"abstract":"Skin laxity in the periorbital region is a common problem that is usually treated surgically. This is not only invasive, but it also increases the risks for the patient and can result in scarring. Innovative therapies involving the use of the most recent generation of interstitial lasers allow for safe, minimally invasive, and effective intervention in patients suffering from blepharochalasis and periorbital bags. A 100% Made in Italy intra-tissue laser lifting technology, in particular, delivers energy to the subcutaneous tissue via laser fibers as small as 200/300 microns, ensuring a targeted release of energy and allowing the formation of new collagen while decreasing skin laxity. The purpose of this study is to assess the effect of an interstitial laser using optical microfibers on 5 patients aged 30 to 60 years. Following anesthesia (Lidocaine and Adrenaline), the treatment was performed using an endotissue laser with a wavelength of 1470 nm. The cumulative energy delivered by the laser by using 300-micron disposable fibers is equal to 200 Joules for each lid, with an infrared thermometer confirming an increase in skin temperature not exceeding 40°C. Over the next six months, patients experienced optimal results with no visible skin signs. In conclusion, we can state that intra-tissue laser lifting can be an effective strategy for the treatment of periorbital laxity, resulting in a decrease in dermal laxity and greater skin homogeneity while ensuring high precision, the absence of superficial incisions, rapid recovery, and optimal results.","PeriodicalId":17981,"journal":{"name":"Laser therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43687934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Whole-cell spectra of human pathogens are examined to identify species-specific wavelengths of maximum light absorption. It is presented how these data relate to clinical efficacy for antimicrobial phototherapies. Twelve species of microorganisms were cultured to exponential growth then processed and suspended in a scattering solution. Diffuse reflectance from the sample was delivered to two spectrometers that covered a spectral range of 370nm to 1200nm. Reflectance spectra were converted to relative absorbance. Absorbance spectra from multiple trials were averaged to produce a representative spectrum for each species. All pathogens studied demonstrated an absorbance spectrum with a primary component in the range 405-426 nm and 1-4 secondary components in the range 445-636 nm. Antibiotic-resistant and antibiotic-sensitive strains of Pseudomonas aeruginosa (Pa) had identical absorbance spectra. Whole-cell spectra support the hypothesis that a pathogen’s absorbance is directly related to efficacy of photoinactivation. The spectral signatures in all pigmented bacteria tested appear to be that of various combinations of in situ porphyrins. The knowledge of the absorption spectrum of a given pathogen provides a logical start for selecting the appropriate light source for a clinical trial.
{"title":"Spectra of pathogens predict lethality of blue light photo-inactivation","authors":"D. Harris","doi":"10.4081/ltj.2023.314","DOIUrl":"https://doi.org/10.4081/ltj.2023.314","url":null,"abstract":"Whole-cell spectra of human pathogens are examined to identify species-specific wavelengths of maximum light absorption. It is presented how these data relate to clinical efficacy for antimicrobial phototherapies. Twelve species of microorganisms were cultured to exponential growth then processed and suspended in a scattering solution. Diffuse reflectance from the sample was delivered to two spectrometers that covered a spectral range of 370nm to 1200nm. Reflectance spectra were converted to relative absorbance. Absorbance spectra from multiple trials were averaged to produce a representative spectrum for each species. All pathogens studied demonstrated an absorbance spectrum with a primary component in the range 405-426 nm and 1-4 secondary components in the range 445-636 nm. Antibiotic-resistant and antibiotic-sensitive strains of Pseudomonas aeruginosa (Pa) had identical absorbance spectra. Whole-cell spectra support the hypothesis that a pathogen’s absorbance is directly related to efficacy of photoinactivation. The spectral signatures in all pigmented bacteria tested appear to be that of various combinations of in situ porphyrins. The knowledge of the absorption spectrum of a given pathogen provides a logical start for selecting the appropriate light source for a clinical trial.","PeriodicalId":17981,"journal":{"name":"Laser therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49372083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Monique Ralph, C. Hurst, S. Guyatt, Kathleen Goldsmith, E. Laakso
The analgesic role of PBMT for breastfeeding women with nipple pain is inconclusive. This study aimed to determine the efficacy of PBMT at 660 nm in postnatal women with nipple pain planning to exclusively breastfeed. A randomised, placebo-controlled clinical study was initiated at a tertiary hospital in Brisbane, Australia on the inpatient maternity wards from May 2020 to September 2020. Eligible participants were randomised into two groups, an intervention group receiving usual care and PBMT (Group A) and a control group receiving usual care and sham PBMT (Group B). Usual care involved consultation with a midwife and/or lactation consultant to assist with infant latching and breastfeeding positioning. PBMT (660 nm; 250 Hz; 17 mW; 0.5 cm2 spot size) was administered three times within 24 hours. Nipple pain was the primary outcome measure analysed using a Visual Analogue Scale (VAS). Quality of life (QoL) and the participants’ perceived efficacy of treatment were secondary outcome measures evaluated using the PROMIS Global Short Form and a combined 5-point Likert scale and thematic analysis, respectively. Due to the impact of COVID-19, only 10 participants were recruited. Compared to sham, three applications of PBMT at 660 nm provided no significant difference to participants’ nipple pain, QoL or perceived efficacy of treatment. Three key themes of PBMT treatment were simplicity, safety and support. This study was unable to demonstrate the impact of PBMT at 660 nm on relieving nipple pain due to low participant numbers. An adequately powered RCT with COVID-19 modifications, is recommended.
{"title":"In postnatal women with nipple pain, does photobiomodulation therapy (PBMT) at 660 nm compared with sham PBMT reduce pain on breastfeeding? A case series during COVID-19","authors":"Monique Ralph, C. Hurst, S. Guyatt, Kathleen Goldsmith, E. Laakso","doi":"10.4081/ltj.2023.315","DOIUrl":"https://doi.org/10.4081/ltj.2023.315","url":null,"abstract":"The analgesic role of PBMT for breastfeeding women with nipple pain is inconclusive. This study aimed to determine the efficacy of PBMT at 660 nm in postnatal women with nipple pain planning to exclusively breastfeed. A randomised, placebo-controlled clinical study was initiated at a tertiary hospital in Brisbane, Australia on the inpatient maternity wards from May 2020 to September 2020. Eligible participants were randomised into two groups, an intervention group receiving usual care and PBMT (Group A) and a control group receiving usual care and sham PBMT (Group B). Usual care involved consultation with a midwife and/or lactation consultant to assist with infant latching and breastfeeding positioning. PBMT (660 nm; 250 Hz; 17 mW; 0.5 cm2 spot size) was administered three times within 24 hours. Nipple pain was the primary outcome measure analysed using a Visual Analogue Scale (VAS). Quality of life (QoL) and the participants’ perceived efficacy of treatment were secondary outcome measures evaluated using the PROMIS Global Short Form and a combined 5-point Likert scale and thematic analysis, respectively. Due to the impact of COVID-19, only 10 participants were recruited. Compared to sham, three applications of PBMT at 660 nm provided no significant difference to participants’ nipple pain, QoL or perceived efficacy of treatment. Three key themes of PBMT treatment were simplicity, safety and support. This study was unable to demonstrate the impact of PBMT at 660 nm on relieving nipple pain due to low participant numbers. An adequately powered RCT with COVID-19 modifications, is recommended.","PeriodicalId":17981,"journal":{"name":"Laser therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45721943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
It is an honour and a pleasure to be writing this Guest Editorial for our journal, Laser Therapy, after 3 years of enforced silence because of what my colleague and friend Glen Calderhead calls “Covidiocy”. We were forced to shut down the Tokyo Editorial Office when Japan went into lockdown in 2019, and suspend publication of the journal, so my Glad News is that Laser Therapy has once again risen like the Phoenix, but this time it’s as an “e-Phoenix” and an e-Journal! I am sure I am speaking for all Laser Therapy readers when I express my sincere gratitude to Professor Leonardo Longo of Florence, Italy, Secretary-General of the World Federation of Societies for Laser Medicine and Surgery (WFSLMS), who has been instrumental in securing a publisher for the re-emergence of the journal in an electronic digital format. Faithful readers will remember from my Editorials in the previous iteration of the journal that we were examining the possibility of moving over from a print version to a digital version, and now thanks to Prof Longo, that goal has been realised. [...]
{"title":"Guest editorial: Happy news and sad news","authors":"T. Ohshiro","doi":"10.4081/ltj.2022.302","DOIUrl":"https://doi.org/10.4081/ltj.2022.302","url":null,"abstract":"It is an honour and a pleasure to be writing this Guest Editorial for our journal, Laser Therapy, after 3 years of enforced silence because of what my colleague and friend Glen Calderhead calls “Covidiocy”. We were forced to shut down the Tokyo Editorial Office when Japan went into lockdown in 2019, and suspend publication of the journal, so my Glad News is that Laser Therapy has once again risen like the Phoenix, but this time it’s as an “e-Phoenix” and an e-Journal! \u0000I am sure I am speaking for all Laser Therapy readers when I express my sincere gratitude to Professor Leonardo Longo of Florence, Italy, Secretary-General of the World Federation of Societies for Laser Medicine and Surgery (WFSLMS), who has been instrumental in securing a publisher for the re-emergence of the journal in an electronic digital format. Faithful readers will remember from my Editorials in the previous iteration of the journal that we were examining the possibility of moving over from a print version to a digital version, and now thanks to Prof Longo, that goal has been realised. [...]","PeriodicalId":17981,"journal":{"name":"Laser therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48616696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We describe a method for fabricating biocompatible chitosan-based adhesives with sub-micron structures to enhance tissue bonding. This procedure avoids coating and chemical modification of structures and requires a simple drop-casting step for the adhesive film formation. Chitosan thin films (27±3 μm) were fabricated with sub-micron pillars (rectangular cuboid with height ∼150 nm, square dimension ∼1 μm and pitch ∼2 μm) or holes (diameter ~500 nm or ~1 μm, depth ~100 or 400 nm, pitch of 1 or 2 μm). Polydimethylsiloxane moulds were used as negative templates for the adhesive solution that was cast and then allowed to dry to form thin films. These were applied on bisected rectangular strips of small sheep intestine and photochemically bonded by a green laser (λ= 532 nm, irradiance ∼110 J/cm2). The tissue repair was subsequently measured using a computer-interfaced tensiometer. The mould sub-micron structures were reproduced in the chitosan adhesive with high fidelity. The adhesive with pillars achieved the highest bonding strength (17.1±1.2 kPa) when compared to the adhesive with holes (13.0±1.3 kPa, p<0.0001, one-way ANOVA, n=15). The production of chitosan films with patterned pillars or holes in the sub-micron range was demonstrated, using a polydimethylsiloxane mould and a single drop-casting step. This technique is potentially scalable to produce adhesives of larger surface areas.
{"title":"Chitosan adhesives with sub-micron structures for photochemical tissue bonding","authors":"Samuel J. Frost, J. Houang, J. Hook, A. Lauto","doi":"10.4081/ltj.2022.306","DOIUrl":"https://doi.org/10.4081/ltj.2022.306","url":null,"abstract":"We describe a method for fabricating biocompatible chitosan-based adhesives with sub-micron structures to enhance tissue bonding. This procedure avoids coating and chemical modification of structures and requires a simple drop-casting step for the adhesive film formation. Chitosan thin films (27±3 μm) were fabricated with sub-micron pillars (rectangular cuboid with height ∼150 nm, square dimension ∼1 μm and pitch ∼2 μm) or holes (diameter ~500 nm or ~1 μm, depth ~100 or 400 nm, pitch of 1 or 2 μm). Polydimethylsiloxane moulds were used as negative templates for the adhesive solution that was cast and then allowed to dry to form thin films. These were applied on bisected rectangular strips of small sheep intestine and photochemically bonded by a green laser (λ= 532 nm, irradiance ∼110 J/cm2). The tissue repair was subsequently measured using a computer-interfaced tensiometer. The mould sub-micron structures were reproduced in the chitosan adhesive with high fidelity. The adhesive with pillars achieved the highest bonding strength (17.1±1.2 kPa) when compared to the adhesive with holes (13.0±1.3 kPa, p<0.0001, one-way ANOVA, n=15). The production of chitosan films with patterned pillars or holes in the sub-micron range was demonstrated, using a polydimethylsiloxane mould and a single drop-casting step. This technique is potentially scalable to produce adhesives of larger surface areas.","PeriodicalId":17981,"journal":{"name":"Laser therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48269798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rosacea is a chronic skin disease prevalently affecting the center of the face. The permanent erythema of skin face represents its typical sign. Further common features are face flushing, telangiectasias, and inflammatory presence of oedema, papules and pustules. The aim of this study was to investigate the use of LBO 532nm laser in the treatment of this disease. Ten subjects of both sex and middle age affected by rosacea in erithemato/teleangectatic stage were treated by a LBO 532nm laser single session. Discomfort evaluation during and after the treatment, one session results as well as incidence of the side effects were evaluated, with 6 months follow up. Positive results were obtained after only one session in total safety with minimal patients discomfort and without undesired effects during treatment. The study confirmed International literature data suggesting the use of laser and light devices as elective treatment of this disease. IPL, dye lasers and 532nm laser are the devices more used and the last seems to represent the gold standard for 1,2,3 phototypes. This clinical trial, with the limitations due to the small number of patients, indicated that “one session LBO 532nm laser treatment” represents an interesting and innovative approach in the therapy of the erythemato/telangectatic rosacea.
{"title":"Fractional treatment of rosacea by LBO 532 nm laser with “one shot” procedure: A preliminary study","authors":"R. Lazzari","doi":"10.4081/ltj.2022.309","DOIUrl":"https://doi.org/10.4081/ltj.2022.309","url":null,"abstract":"Rosacea is a chronic skin disease prevalently affecting the center of the face. The permanent erythema of skin face represents its typical sign. Further common features are face flushing, telangiectasias, and inflammatory presence of oedema, papules and pustules. The aim of this study was to investigate the use of LBO 532nm laser in the treatment of this disease. Ten subjects of both sex and middle age affected by rosacea in erithemato/teleangectatic stage were treated by a LBO 532nm laser single session. Discomfort evaluation during and after the treatment, one session results as well as incidence of the side effects were evaluated, with 6 months follow up. Positive results were obtained after only one session in total safety with minimal patients discomfort and without undesired effects during treatment. The study confirmed International literature data suggesting the use of laser and light devices as elective treatment of this disease. IPL, dye lasers and 532nm laser are the devices more used and the last seems to represent the gold standard for 1,2,3 phototypes. This clinical trial, with the limitations due to the small number of patients, indicated that “one session LBO 532nm laser treatment” represents an interesting and innovative approach in the therapy of the erythemato/telangectatic rosacea.","PeriodicalId":17981,"journal":{"name":"Laser therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48727787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chen-Jen Chang, Yen-Chang Hsiao, Ana Elena Aviña, Yu-fan Chiang
Rosacea is a chronic dermatosis with no cure. Our goal was to evaluate if the combination of flashlamp-pumped Pulsed Dye Laser (PDL) treatment with topical imiquimod could improve therapeutic outcomes. Fourty patients diagnosed with rosacea and aged between 16 and 53 years were assigned for three different types of treatment: i) PDL-only, ii) imiquimod-only, and iii) PDL + imiquimod. The PDL test sites received a single treatment with the VBeam laser (λ = 595 nm; spot size = 7 mm; tp = 1500 msec) at a dosage of 10 J/cm2 with cryogen spurt duration (30 msec) and the delay time (20 msec). For the test sites of PDL + imiquimod and imiquimod-only, the patients applied imiquimod topically to the test sites once a day for 1 month. Patients were followed-up at 1, 3, and 6 months. The primary efficacy was measured with a DermoSpectrometer. Patients were also monitored for adverse effects. Pair-wise analysis showed statistically significant differences between the blanching responses for the PDL + imiquimod and PDL-only and imiquimod-only treatments (p<0.005). Transient hyperpigmentation was noted in 5% (n=2) and 20% (n=8) of patients in the PDL + imiquimod and PDL-only treatment, respectively. Hyperpigmentation resolved spontaneously within 6 months. Permanent hypopigmentation or scarring was not observed. Superior blanching responses were obtained when using PDL + imiquimod than PDL-only or imiquimod-only treatment for rosacea. A larger number of patients are required to support the results of this study.
{"title":"The effectiveness of flashlamp-pumped pulsed dye laser in conjunction with topical imiquimod treatment for rosacea","authors":"Chen-Jen Chang, Yen-Chang Hsiao, Ana Elena Aviña, Yu-fan Chiang","doi":"10.4081/ltj.2022.303","DOIUrl":"https://doi.org/10.4081/ltj.2022.303","url":null,"abstract":"Rosacea is a chronic dermatosis with no cure. Our goal was to evaluate if the combination of flashlamp-pumped Pulsed Dye Laser (PDL) treatment with topical imiquimod could improve therapeutic outcomes. Fourty patients diagnosed with rosacea and aged between 16 and 53 years were assigned for three different types of treatment: i) PDL-only, ii) imiquimod-only, and iii) PDL + imiquimod. The PDL test sites received a single treatment with the VBeam laser (λ = 595 nm; spot size = 7 mm; tp = 1500 msec) at a dosage of 10 J/cm2 with cryogen spurt duration (30 msec) and the delay time (20 msec). For the test sites of PDL + imiquimod and imiquimod-only, the patients applied imiquimod topically to the test sites once a day for 1 month. Patients were followed-up at 1, 3, and 6 months. The primary efficacy was measured with a DermoSpectrometer. Patients were also monitored for adverse effects. Pair-wise analysis showed statistically significant differences between the blanching responses for the PDL + imiquimod and PDL-only and imiquimod-only treatments (p<0.005). Transient hyperpigmentation was noted in 5% (n=2) and 20% (n=8) of patients in the PDL + imiquimod and PDL-only treatment, respectively. Hyperpigmentation resolved spontaneously within 6 months. Permanent hypopigmentation or scarring was not observed. Superior blanching responses were obtained when using PDL + imiquimod than PDL-only or imiquimod-only treatment for rosacea. A larger number of patients are required to support the results of this study.","PeriodicalId":17981,"journal":{"name":"Laser therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48146793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lasers and others energy-based devices have reached very high levels of results. Although the area of the lower eyelids is one of the most difficult to treat without surgery, Endolift® represents one of the safest and effective techniques that we can offer. Endolift® procedure was performed with a 200 microns second-generation bare fiber connected to an Italian 1470nm semiconductor laser to treat the lower eyelids of a 43-year-old patient with wrinkles and skin laxity. No anesthesia was required. The fiber was easily inserted through the skin, without any incisions, directly between the orbicularis oculi muscle and the septum. The total laser energy delivered was 80 J for each side. Post-procedure the patient immediately resumed her daily activities. Snap Back test was performed before (T0) and 6 months (T1) after the procedure; Fitzpatrick “wrinkle score” and “degree of elastosis” were assessed at T0 and T1; investigator Global Aesthetic Improvement scale (iGAIS), external investigator Global Aesthetic Improvement scale (eiGAIS) and participant Global Aesthetic Improvement scale (pGAIS) were also recorded at T1. The treatment has been completed with a session of a vascular 532nm diode laser for treating the fine telangiectasias, immediately before the Endolift® procedure. The lower eyelids have benefited from the possibility that the Endolift® has to remodel and retract the tissues, activate the collagen production, and stimulate the neo-angiogenesis. Results are evaluated at T1, when the skin laxity is reduced and superficial wrinkles are smoothed, resulting in an overall compacting of the skin which is visible and continues to progress over the following months. The only adverse events recorded were redness for 3 hours and a light swelling for 2 days. Snap Back test at T0 was severe and negative at T1; at T0 wrinkle score” was II and Fitzpatrick “degree of elastosis” was 7-9 but at T1 Fitzpatrick “wrinkle score” was I and Fitzpatrick “degree of elastosis” was 1-3; iGAIS, eiGAIS and pGAIS at T1 were all +3. Endolift® can currently be considered one of the leading non-surgical treatments for the laxity of lower eyelids.
{"title":"Endolift® the “lunch-time” laser lifting for the lower eyelids","authors":"R. Dell'avanzato","doi":"10.4081/ltj.2022.307","DOIUrl":"https://doi.org/10.4081/ltj.2022.307","url":null,"abstract":"Lasers and others energy-based devices have reached very high levels of results. Although the area of the lower eyelids is one of the most difficult to treat without surgery, Endolift® represents one of the safest and effective techniques that we can offer. Endolift® procedure was performed with a 200 microns second-generation bare fiber connected to an Italian 1470nm semiconductor laser to treat the lower eyelids of a 43-year-old patient with wrinkles and skin laxity. No anesthesia was required. The fiber was easily inserted through the skin, without any incisions, directly between the orbicularis oculi muscle and the septum. The total laser energy delivered was 80 J for each side. Post-procedure the patient immediately resumed her daily activities. Snap Back test was performed before (T0) and 6 months (T1) after the procedure; Fitzpatrick “wrinkle score” and “degree of elastosis” were assessed at T0 and T1; investigator Global Aesthetic Improvement scale (iGAIS), external investigator Global Aesthetic Improvement scale (eiGAIS) and participant Global Aesthetic Improvement scale (pGAIS) were also recorded at T1. The treatment has been completed with a session of a vascular 532nm diode laser for treating the fine telangiectasias, immediately before the Endolift® procedure. The lower eyelids have benefited from the possibility that the Endolift® has to remodel and retract the tissues, activate the collagen production, and stimulate the neo-angiogenesis. Results are evaluated at T1, when the skin laxity is reduced and superficial wrinkles are smoothed, resulting in an overall compacting of the skin which is visible and continues to progress over the following months. The only adverse events recorded were redness for 3 hours and a light swelling for 2 days. Snap Back test at T0 was severe and negative at T1; at T0 wrinkle score” was II and Fitzpatrick “degree of elastosis” was 7-9 but at T1 Fitzpatrick “wrinkle score” was I and Fitzpatrick “degree of elastosis” was 1-3; iGAIS, eiGAIS and pGAIS at T1 were all +3. Endolift® can currently be considered one of the leading non-surgical treatments for the laxity of lower eyelids.","PeriodicalId":17981,"journal":{"name":"Laser therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43878210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：